Key Highlights

  • Clover Health (NASDAQ:CLOV) was up 11.35% in premarket trading on October 9, 2026 on a listed price of USD 4.58 and a Market Value of about USD 2.43 billion.
  • No Clover-specific announcement was found for October 8 or 9; the screener tags the move as news, and the likeliest backdrop is the October 8 CMS star ratings release that moved Humana and Alignment.
  • Second-quarter 2026 Revenue rose 55.6% to USD 743.2 million and Net Income was USD 28.0 million against a loss of USD 10.6 million a year earlier, per the company release of August 5.
  • Full-year guidance was raised to revenue of USD 2.92 billion to USD 3.00 billion and adjusted EBITDA of USD 70 million to USD 85 million, with membership of 157,309 at June 30.

What Moved Clover Shares

Clover Health (NASDAQ:CLOV) was indicated up 11.35% in the October 9, 2026 premarket session on the screener, on a listed price of USD 4.58 and premarket Volume of 40,045 shares. The screener tags the catalyst as news, but a search found no company release, filing or analyst note dated October 8 or 9, so the cause is unconfirmed. The most relevant backdrop is the Centers for Medicare and Medicaid Services 2027 Star Ratings, published October 8, 2026, which lifted Humana's largest contract and cut Alignment Healthcare's. Reports reviewed did not show Clover's own contract ratings, so any link between those ratings and this move is an inference, not a finding.

Results and Guidance Behind the Stock

Clover's last report, on August 5, 2026, showed second-quarter revenue of USD 743.2 million, up 55.6% from USD 477.6 million, and net income of USD 28.0 million against a net loss of USD 10.6 million a year earlier. Adjusted EBITDA rose 139.2% to USD 40.9 million. Insurance membership reached 157,309 at June 30 from 106,323 a year earlier. Management raised full-year guidance to revenue of USD 2.92 billion to USD 3.00 billion, adjusted EBITDA of USD 70 million to USD 85 million and GAAP net income of USD 20 million to USD 35 million. The release cited the flexibility of a 4.5 star payment year in its 2027 outlook.

Risks and What to Watch

Medicare Advantage margins depend on medical costs, risk adjustment and star ratings, and the sector just showed how one rating decision can move shares by 15% to 23% in either direction, as Humana and Alignment did. Clover Health (NASDAQ:CLOV) lists its ability to maintain or improve star ratings among its risk factors. Rapid membership growth can also strain claims forecasting, and a 4.5 star payment year can change in later cycles. Investors should read Clover's contract-level ratings when available, watch the next Quarterly Report and compare cost trends with larger peers. A premarket gain on 40,045 shares is a thin quote that may reverse at the open.

Where Things Stand

Clover Health (NASDAQ:CLOV) is up in premarket, but no company announcement was found, so the cause is unconfirmed; the likeliest context is sector attention after the October 8 star ratings release, which is an inference. The fundamentals look strong on paper: second-quarter revenue up 55.6%, positive net income and a raised outlook. The balance of evidence is that this is a sympathy or momentum move on thin volume rather than a company-specific event. The next checkpoints are Clover's own contract ratings, any filing and the next Earnings report.